Noxibel

Quick links to important sections

Noxibel

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noxibel

Noxibel is a prescription-only medication indicated for the treatment of episodes of major depressive disorder (MDD) in adults. Its single active ingredient is mirtazapine. It is manufactured by pharmaceutical companies like Gramón Bagó and is available as an oral tablet in various strengths.


Quick Facts about Noxibel

Property Description
Active ingredient Mirtazapine
Form Oral tablet (various strengths)
Pharmacological Class Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)
Common Use Treatment of Major Depressive Disorder (MDD)

Classification and Distinctive Action

Noxibel belongs to a unique category of psychiatric drugs known as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). This classification reflects a distinct mechanism of action that differentiates it from more commonly known antidepressants, such as SSRIs (Selective Serotonin Reuptake Inhibitors).

This specific mechanism—which involves blocking certain brain receptors—is clinically recognized for enhancing the activity of key mood-regulating neurotransmitters: norepinephrine and serotonin. This effect helps restore chemical balance in the brain, alleviating symptoms of depression.

Prescription Status and Patient Profile

As a federally-regulated pharmaceutical, Noxibel must only be taken under the guidance and prescription of a licensed healthcare provider. Mirtazapine is approved for treating Major Depressive Disorder.

Due to its potent antihistamine properties (a unique feature of the drug), physicians sometimes select Noxibel for patients whose depression is accompanied by prominent symptoms of insomnia or poor appetite. This specific side effect profile often makes it a suitable choice for a particular patient group.

What side effects are possible with Noxibel?

The following information describes the officially documented adverse reactions and safety characteristics of Noxibel (mirtazapine), strictly based on government regulatory sources. Safety classifications are organized by frequency and physiological system as defined in official labeling.


Classification of Adverse Reactions

Very Common Adverse Reactions (occurring in geq 1 in 10 patients): Reactions frequently reported relate primarily to the Central Nervous System and Metabolism. These include somnolence (drowsiness) or sedation, increased appetite, weight gain, headache, and dry mouth.

Common Adverse Reactions (occurring in geq 1 in 100 to < 1 in 10 patients): Common effects involve the Nervous, Gastrointestinal, and Musculoskeletal Systems. Examples include dizziness, tremor, confusion, lethargy, nausea, vomiting, constipation, joint pain (arthralgia), muscle pain (myalgia), and peripheral swelling (oedema).


Serious Safety Considerations

Official regulatory documentation highlights several potentially serious adverse reactions, though these are classified as rare. These include a risk of Agranulocytosis, a severe reduction in white blood cells, which has been reported mainly after four to six weeks of treatment. The risk of Serotonin Syndrome, a potentially serious condition associated with mental status changes and autonomic instability, is also noted. Furthermore, the label carries a mandated regulatory warning concerning the increased risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18–24) during initial treatment or dose changes.


Time- and Population-Related Safety Notes

Safety notes specify that sedation and orthostatic hypotension are typically more common during the initial weeks of treatment. Weight gain is frequently associated with longer-term exposure. Specific caution is advised for older adults due to potential increased sensitivity to certain documented adverse effects and for patients with moderate to severe hepatic or renal impairment due to reduced drug clearance.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for a Noxibel (mirtazapine) overdose outlines specific manifestations and mandated emergency actions based on authoritative government documentation.

Domain Official Regulatory Statement
Documented Overdose Presentations Symptoms include CNS depression, presenting as drowsiness, disorientation, somnolence, and lethargy.
Physiological Systems Affected Primarily the central nervous system (CNS) and cardiovascular system, with the most common effect being tachycardia.
Dose-related or Exposure-related Factors Overdose is generally considered mild when mirtazapine is taken alone, but is more severe in cases of mixed overdose with other substances, including alcohol.
When immediate medical help is required Seek immediate medical attention for all suspected cases of overdose. Contact emergency services or a poison control center immediately.

Classification Aspect Official Regulatory Statement
Severity Classification Documented outcomes range up to serious or potentially life-threatening manifestations like convulsions, coma, and Serotonin Syndrome.
Overdose-Context Constraints No specific antidote is known. Management consists of symptomatic and supportive treatment and requires prolonged medical observation.

Official Overdose Statements

  • Overdose may present with documented clinical manifestations including disorientation, drowsiness, and tachycardia.
  • Severe or potentially life-threatening manifestations include convulsions, cardiac arrhythmias, and Serotonin Syndrome.
  • In all cases of suspected overdose, the mandated action is to seek immediate medical attention and initiate symptomatic and supportive treatment.

Connection to the overall overdose profile: Regulatory documents define the Noxibel overdose profile by its CNS and cardiovascular effects and mandate that urgent medical help must be sought for any suspected overdose because of the risk of severe outcomes and the necessary requirement for prolonged monitoring and supportive care. The official instructions confirm that no specific antidote is available.

Therapeutic Uses of Noxibel

What Noxibel Treats: Main Uses and Benefits

Noxibel (mirtazapine) is a prescription medication used to manage the symptoms of Major Depressive Disorder (MDD) in adults. It provides targeted symptomatic support across the key domains of the illness and may assist with managing the overall symptom load.

The medication is commonly used to address conditions characterized by episodic or fluctuating manifestations, and it plays a role in managing symptoms related to: core mood distress (sadness and anhedonia), severe sleep disruption (insomnia), and appetite loss associated with depression. This focus on both psychological and physical symptoms makes it relevant when supportive symptom management is appropriate.

Targeted Relief and Symptom Clusters

Noxibel is generally applied when symptoms create noticeable functional strain. It assists with managing symptom clusters that may become intense or disruptive, such as the combination of persistent low mood with significant insomnia and pronounced appetite loss associated with depression. By moderating these distressing manifestations, the medication assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Vegetative Symptoms Noxibel is commonly used to help with decreased appetite and sleep disturbances, contributing to improved physical comfort during periods of heightened symptoms.


Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Noxibel

The eligibility for Noxibel (mirtazapine) is strictly defined by regulatory guidelines, classifying patients into three groups: prohibited, allowed, and restricted.

Classification Eligibility Criteria (Regulatory Wording)
Prohibited (Contraindicated) Patients with known hypersensitivity to mirtazapine or excipients. Patients taking, or who have discontinued within the last 14 days, a Monoamine Oxidase Inhibitor (MAOI).
Allowed (Age) Use is indicated only for adults (18 years and older). Safety and effectiveness have not been established in children and adolescents.
Restricted (Conditional Use) Use requires caution and close monitoring in patients with moderate to severe renal or hepatic impairment due to reduced drug clearance. Caution is also advised for older adults and those with a history of mania/hypomania, cardiovascular conditions (including QTc risk), or angle-closure glaucoma.

Pregnancy and Lactation Eligibility: Use during pregnancy should occur only if clearly needed. Mirtazapine is found in small amounts in breast milk; use requires monitoring of the infant. Regulatory documents define who can and cannot use the medicine by establishing absolute contraindications and conditional requirements based on organ function and comorbidities.

What should I know about interactions with other medicines?

The use of Noxibel with certain other medications or substances can result in significant interactions, requiring careful monitoring or avoidance.

Contraindicated and High-Risk Combinations

Interacting Product Category Rationale & Restriction
Monoamine Oxidase Inhibitors (MAOIs) Concomitant use is contraindicated, including within 14 days of stopping an MAOI. This combination carries a risk of serious reactions, including serotonin syndrome, which involves symptoms like agitation, rapid heart rate, and confusion.
Other Serotonergic Drugs Co-administration with other medicines that increase serotonin (e.g., triptans, linezolid, St. John's wort) should be approached with caution due to the heightened risk of developing serotonin syndrome.

Interactions Affecting Drug Concentration

Noxibel is metabolized by certain liver enzymes (primarily CYP3A4, CYP2D6, and CYP1A2). Interactions that alter these enzymes can change the concentration of Noxibel in the body:

  • Strong CYP3A Inducers (e.g., carbamazepine, phenytoin): These medicines increase the breakdown of Noxibel, which may lead to lower effectiveness. A dosage increase of Noxibel may be required.
  • Strong CYP3A Inhibitors (e.g., certain antifungals like ketoconazole, HIV protease inhibitors, and Cimetidine): These medicines slow the breakdown of Noxibel, potentially increasing its concentration and the risk of side effects. A dosage decrease may be necessary.

Other Notable Interactions

  • Warfarin (an anticoagulant): When taken together, Noxibel may affect the patient’s ability to clot blood, necessitating the close monitoring of the International Normalized Ratio (INR).
  • Central Nervous System (CNS) Depressants (e.g., alcohol, benzodiazepines): Combining these products may result in excessive sedation and impairment.

Mechanism of Action

Noxibel's mechanism of action is defined by its activity as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA), involving three primary pharmacological domains in the central nervous system.

Its initial action is an antagonistic blockade of presynaptic α2-adrenergic autoreceptors and heteroreceptors. Occupying these sites removes the natural inhibitory brake on neurotransmitter release, thereby increasing the synaptic availability of both norepinephrine and serotonin simultaneously. This fundamental action is applied in contexts involving the modulation of central regulatory pathways.

Concurrently, the molecule blocks postsynaptic 5-HT2 and 5-HT3 receptors. This targeted antagonism causes the increased synaptic serotonin to be preferentially directed toward 5-HT1 A receptors, modifying molecular steps and contributing to altered signaling dynamics within the serotonergic pathway.

A key feature of the drug's profile is its antagonistic effect at Histamine H1 receptors in the brain. This high-affinity interaction modifies activity within the histaminergic system, resulting in the physiological consequence of suppressed central arousal.

Dosage and Administration Information

Noxibel (mirtazapine) is administered exclusively via the oral route and is available as a film-coated tablet and an orally disintegrating tablet (ODT) in various strengths, typically ranging up to 45 mg. The standard adult regimen for treatment initiation is 15 mg once daily. This daily dose may be adjusted within the effective range of 15 mg to a maximum of 45 mg.

Administration Guidelines

The prescribed dose is generally taken once per day, preferably in the evening prior to bedtime, due to the drug’s properties. Dosing is independent of meals, meaning it can be taken with or without food.

Procedural Instruction Requirement
Dose Titration Adjustments to the daily dose should occur at intervals of no less than 1 to 2 weeks to allow for proper evaluation.
Tablet Use Film-coated tablets must be swallowed whole with fluid; they should not be chewed. ODT forms require handling with dry hands.

Population-Specific Use

Official instructions require specific procedural adjustments for certain patient groups. Treatment in older adults should generally begin at a lower starting dose and necessitate closer supervision during any dose adjustment process. Additionally, a dose decrease is required for patients diagnosed with moderate to severe renal or hepatic impairment to manage drug clearance.

The overall use protocol establishes that after achieving an initial response, treatment should be continued for a period of at least six months to consolidate the benefit. When treatment is stopped, the dose must be reduced gradually.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Noxibel


Evidence from Short-Term Trials for Major Depressive Disorder (MDD)

Short-term randomized controlled trials (RCTs) form a core part of the evidence for Noxibel (mirtazapine). These are the standard study design where adult participants with Major Depressive Disorder (MDD) were randomly assigned to receive either the active medication, an inactive placebo (a sugar pill), or sometimes another antidepressant for a defined period.

Researchers used standardized clinical scales in studies exploring how symptoms change over time and how the intensity of depression is measured. Research explored the overall patterns of symptoms over these short periods, which typically lasted between four and twelve weeks. Studies focusing on research scenarios involving fluctuating or unstable symptoms also examined specific outcomes related to physical discomfort, such as those related to sleep disturbance and appetite within the depression scales.

Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations over the short-term study periods. Comparative research with other antidepressants reported different patterns of symptom evolution over the defined study time intervals. These short-term findings help contextualize how patients reported their experience during the initial phase of treatment.


Long-Term Studies and Maintenance of Response

While the initial trials focus on the acute (short-term) phase of depression, other studies have explored the question of maintenance of response—whether observed patterns can be sustained over a longer period. These were continuation trials where adults who initially responded well to the drug were then randomized again to either keep taking Noxibel or switch to a placebo.

These long-term studies monitored sustained functional balance and evaluated the rate or time to relapse (the return of a major depressive episode) over periods of up to 40 weeks. The long-term research describes patterns where the continuation of the medication was associated with observed variations in the rate of relapse compared to those switched to placebo during the observation phase.

However, long-term effects are not fully established for all populations, and there is limited information for outcomes extending beyond these specific trial durations. The findings from these studies help show what has been observed so far in patients who were already stabilized, but research findings cannot predict whether an individual will respond similarly or avoid relapse.


Evidence in Specific Patient Groups and Populations

The core research population was generally adult outpatients diagnosed with MDD. However, some studies have evaluated the drug in more specific groups. For instance, older adults were evaluated in some research settings to observe symptom patterns and tolerability in this demographic.

Research examined its use in patients with conditions associated with acute or disruptive episodes, specifically focusing on outcomes related to sleep disturbance and appetite within the depression scales. Additionally, research has explored groups who have experienced prior treatment failure with other types of antidepressants, examining how symptoms evolve in these specific observed populations.

Research describes the specific symptom changes and outcomes related to physical discomfort in these subgroups. However, subgroup findings are uncertain due to the limited number of studies and the tendency for initial trials to exclude individuals with complex medical conditions or severe, unstable comorbidities.


Limitations, Consistency, and Areas of Research Uncertainty

The evidence landscape for the acute use of Noxibel in MDD is characterized by multiple RCTs and subsequent meta-analyses, which include the most rigorous study types (RCTs) for the core indication. However, it is important to understand the limitations inherent in this research.

Most of the initial effectiveness data for the acute phase comes from studies where follow-up durations were limited (often only 6 weeks). This means that long-term outcomes are not fully established beyond the short-term and maintenance study periods. Furthermore, while comparative evidence against placebo is clear, comparative evidence is lacking for direct, long-term comparisons against all currently available new-generation antidepressants.

The results apply only to the populations studied, which are often defined by strict inclusion criteria that do not represent all people living with depression. Evidence quality varies across studies, and data for certain groups remain insufficient. This highlights that while research describes patterns related to short-term changes, certainty remains low for many specific long-term scenarios.

Frequently Asked Questions (FAQ)

Common questions about Noxibel (FAQ)


Q: How quickly does Noxibel start to work?

Studies used to establish the effectiveness of the medicine typically evaluated changes over periods lasting between four and twelve weeks. Dose adjustments, if needed, are generally made at intervals of no less than one to two weeks, which is the period defined in the label for observing the initial response.


Q: How long does the effect of Noxibel typically last?

The prescribed dosage is generally taken once per day. The drug's properties support once-daily dosing, which means the prescribed dose is generally taken once every 24 hours.


Q: Can Noxibel cause weight gain?

According to official product information, increased appetite and weight gain are classified as Very Common Adverse Reactions, meaning they are reported in at least 1 in 10 patients. Weight gain is noted to be frequently associated with longer-term use of the drug.


Q: Is it common to feel sleepy when taking Noxibel?

Somnolence (drowsiness) or sedation is classified as a Very Common Adverse Reaction, reported in at least 1 in 10 patients. Official safety notes indicate this effect is typically more common during the initial weeks of treatment with the medicine.


Q: What happens if I forget to take a dose of Noxibel?

Official patient information outlines a procedure: if a dose is forgotten, the instruction is to take it as soon as it is remembered, unless it is almost time for the next dose. If so, the missed dose is omitted to maintain the prescribed schedule.


Q: Can Noxibel affect the liver or kidneys?

Regulatory documents indicate that patients with moderate to severe renal or hepatic impairment (reduced kidney or liver function) may require dose adjustments. This is because the drug's clearance (how it is removed from the body) may be reduced in these circumstances.


Q: Does Noxibel interact with common cold medicines?

Caution is advised when using Noxibel with other medicines that act as Central Nervous System (CNS) depressants, which can include certain antihistamines found in some cold or allergy products. Combining these products may result in excessive sedation and impairment.


Q: Is there a generic version of Noxibel available?

Yes, the active ingredient in Noxibel, which is mirtazapine, is available as a generic drug approved by various regulatory agencies, including the FDA.


Q: How does Noxibel differ from similar medications in its class?

Noxibel is classified as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). Its unique mechanism of action involves the blocking of specific brain receptors, including Histamine H1 receptors, which distinguishes its pharmacological profile from other common antidepressant classes.


Q: Can Noxibel affect my driving ability?

Due to the potential for common side effects like somnolence and sedation, regulatory documents caution that the drug may affect a person's ability to operate machinery or drive a car. This possibility is highlighted particularly during the initial weeks of treatment.


Q: Does Noxibel need to be tapered off when stopping use?

Regulatory documents state that when stopping treatment, the dose should be reduced gradually. Abrupt discontinuation may be associated with certain symptoms, such as dizziness, agitation, anxiety, abnormal dreams, or headache.


Q: What is the recommended period of time to use Noxibel?

Official administration instructions state that after an initial clinical response is achieved, treatment should be continued for a period of at least six months. The stated aim of this continuation is to help maintain the initial response.


Q: Does taking Noxibel require regular blood tests?

Routine testing is generally not required; however, official documents advise that if a patient develops symptoms like fever, sore throat, or other signs of infection, they should immediately inform a healthcare provider. This is necessary for a potential blood test, as regulatory documents note a rare, serious condition involving a severe reduction in white blood cells (Agranulocytosis).


Q: What is the meaning of the active ingredient name in Noxibel?

The active ingredient, mirtazapine, is a synthetic tetracyclic derivative. It belongs to the piperazino-azepines class, which refers to its specific chemical structure. This structure is tied to its unique action as an antidepressant.


Q: How long has Noxibel been available on the market?

The active ingredient in Noxibel, mirtazapine, was first approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States in June 1996.


Q: What were the primary endpoints in the clinical trials for Noxibel?

The primary measures used to evaluate effectiveness in short-term clinical trials were typically the change in the total score on standardized depression scales. Examples include the Hamilton Depression Rating Scale-17 (HAMD-17) or the Clinical Global Impression-Severity (CGI-S) scale.


Q: Is the effectiveness of Noxibel consistent across all age groups?

Clinical trials for the core use were primarily conducted in adult outpatients. While older adults were evaluated in some research, official regulatory summaries generally do not provide a conclusive statement on the consistency of effectiveness across all adult age groups.


Q: Does Noxibel impact fertility?

Based on available clinical information, the impact of the active ingredient on fertility in men or women is generally considered limited or not established.


Q: Can men and women use Noxibel in the same way?

The recommended dosing and administration guidelines provided in regulatory documents are based on factors like age and organ function (e.g., kidney or liver health). No specific differences in dosing or administration are noted based on the patient's sex.


Q: What should I do in the case of a suspected overdose of Noxibel?

Regulatory guidance describes the procedure as immediately contacting a poison control center or local emergency medical services (such as 911 in the U.S.) in the case of a suspected overdose.


Q: Is it true that Noxibel needs to be taken at a specific time of day?

The prescribed dose is generally taken once per day. It is commonly recommended to be taken in the evening prior to bedtime because of its potential to cause drowsiness.


Q: What if Noxibel doesn't seem to be working for me after a few days?

It is recognized that the full effects of this type of medication can take up to a few weeks before an improvement is noticed. Official administration guidelines state that dose adjustments should occur at intervals of no less than one to two weeks.


Q: Does Noxibel affect blood sugar levels?

Official warnings note that for patients with diabetes, the drug can make it more difficult to maintain stable blood sugar levels. Monitoring of blood glucose may be recommended for these individuals.


Q: Is Noxibel used for mental health conditions?

Noxibel is approved by regulatory agencies only for the treatment of episodes of major depressive disorder (MDD) in adults. Official documents do not list approval for other mental health conditions.


Q: Are there any known long-term effects of taking Noxibel?

Clinical trials have evaluated the drug's effects over a period of up to 40 weeks. Regulatory documents state that the full long-term effects beyond this period are not fully established for all patient populations, and research findings are limited for outcomes extending past the defined study durations.


Q: Can Noxibel be used during pregnancy?

Official documents state that use during pregnancy should occur only if clearly needed. Regulatory documents advise that taking the medicine in the later stages of pregnancy might cause short-term withdrawal symptoms in the baby after birth, who will be monitored by medical staff.


Q: Is Noxibel safe to use while breastfeeding?

The active ingredient in Noxibel passes into breast milk in small amounts. Use while breastfeeding requires the infant to be monitored for possible side effects, such as changes in behavior or adequate weight gain.


Q: Why are people talking about Noxibel causing sleep problems?

The drug's mechanism of action includes a strong antagonistic effect on Histamine H1 receptors in the brain. This action is associated with the side effect of sedation or somnolence, which is why the drug is sometimes selected for patients whose condition includes symptoms of insomnia.


Q: Is it better to take Noxibel with food or on an empty stomach?

According to official administration instructions, the dosing is independent of meals. This means the medicine can be taken with or without food.


Q: What should I do if I experience a rash while taking Noxibel?

The occurrence of a rash or other signs of hypersensitivity is a reason to seek medical attention. Official warnings state that if a severe reaction is suspected, the regulatory guidance is to discontinue the drug and seek immediate medical help.


Q: What kind of studies have been done on Noxibel?

Studies supporting the drug's approved use include Short-Term Randomized Controlled Trials (RCTs), which compared the medicine to an inactive placebo pill. Also, long-term continuation trials were conducted to study the maintenance of a response and prevention of relapse.

How should Noxibel be stored and disposed of?

How to Store and Dispose of Noxibel?

Noxibel (mirtazapine) must be stored and disposed of according to specific regulatory requirements to maintain product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20^circ to 25 C (68^circ to 77 F).
Protection Keep protected from light and moisture.
Container Keep in the original container, tightly closed, and avoid storage in the bathroom.
Child Safety Must be stored out of the sight and reach of children.
ODT Integrity Orally Disintegrating Tablets (ODT) must be used immediately upon opening the individual blister pack.

Disposal Instructions

Expired or unused Noxibel should be disposed of via a drug take-back program or an authorized collector. If these programs are unavailable, the medicine must be mixed with an unappealing substance, sealed in a bag, and then placed into the household trash. Do not dispose of this medicine by flushing it down the toilet or pouring it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noxibel found in:

A-Z Index: